logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
D

Dongqing Lv

Wenzhou Medical University
H指数:25
被引数:2,646

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Efficacy and safety of first-line osimertinib in Chinese patients with EGFR-mutated advanced non-small cell lung cancer: a prospective, multicenter, non-interventional study (FLOURISH)

奥希替尼作为一线治疗在中国表皮生长因子受体突变阳性晚期非小细胞肺癌患者中的有效性和安全性：一项前瞻性、多中心、非干预性研究（FLOURISH）

Cancer Biology & Medicine
IF8.4
2026-05-010
PRE
Shen, Lisha; Lv, Dongqing; Tang, Ke-Jing; Zhao, Jun; Zhu, Dan; Zhao, Yanqiu; Wang, Ke; Wang, Yan; Cai, Zhigang; Xing, Ligang; Xie, Ke; Cui, Jiuwei; Mu, Lin; Cao, Chao; Ding, Liren; Chen, Peifeng; Liang, Jun; Ding, Yongmin; Lu, Liqin; Zhang, Jiliang; Yu, Xinmin; Chen, Li; Zheng, Jing; Zhou, Jianya; Zhou, Jianying
Identification of subtypes and construction of a predictive model for novel subtypes in severe community-acquired pneumonia based on clinical metagenomics: a multicenter; retrospective cohort study

基于临床宏基因组学的重症社区获得性肺炎亚型识别及新型亚型的预测模型构建：一项多中心回顾性队列研究

Frontiers in Cellular and Infection Microbiology
IF4.8
2025-12-090
OAAI
Shiyi Chen†; Yongpo Jiang†; Dongqing Lv†; Ye Zheng; Ruihai Zhang; Hanzhi Dai; Ziyi Wang; Shuyang Li; Rongbin Qi; Hailing Xu; Yingying Yu; Cailin Xu; Xuanyu Lu; Yinghe Xu; Shengwei Jin; Xiaomai Wu
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy

PACIFIC-5: 在不可切除的III期NSCLC患者中巩固durvalumab的III期临床试验，同时或序贯放化疗后无进展

Journal of Hematology & Oncology
IF40.4
2025-12-070
OAAI
Yi-Long Wu; Lin Wu; Nan Bi; Timucin Cil; Hong Ge; Zhengfei Zhu; Chih-Liang Wang; Wei Zhang; Dongqing Lv; E. Mingyan; Jianguo Sun; Yi Pan; Maciej Krzakowski; Mustafa Dikilitas; Mehmet Ali Nahit Sendur; Young-Chul Kim; Yanjiao Yang; Rui Mao; Biao Zhang; Luhua Wang
Andamertinib in Advanced Non-Small-Cell Lung Cancer with EGFR Exon 20 Insertions After Platinum-Based Chemotherapy or Immunotherapy: Results from the Phase 2 KANNON Study

安达曲尼布在EGFR外显子20插入的晚期非小细胞肺癌患者中的应用：铂类为基础的化疗或免疫治疗后的KANNON II期研究结果

Journal of Thoracic Oncology
IF20.8
2025-11-150
OAAI
Jin-Ji Yang; Yu Mu; Zhe-Hai Wang; Jian-Chun Duan; Yan Zhang; Lin Wu; Hua Zhong; Jun Zhao; Yu Yao; Ping Wang; Xiao-Ling Li; Run-Xiang Yang; Xu-Hong Min; Dong-Qing Lv; Hai-Peng Xu; Zhen-Ming Fu; Bo Shen; Long-Hua Sun; Chang-Li Wang; Jian-Ya Zhou
Quantitative and Dynamic ctDNA as a Biomarker of Response and Survival in Patients With Advanced Lung Squamous Cell Carcinoma Receiving Immunochemotherapy or Chemotherapy Alone

定量和动态循环肿瘤DNA作为接受免疫化疗或单纯化疗的晚期肺鳞状细胞癌患者中反映疗效和生存的生物标志物

Journal of Thoracic Oncology
IF20.8
2025-06-030
PRE
Fei Zhou; Jiao Zhang; Shengxiang Ren; Jianhua Chen; Feifei Li; Ting Ma; Yong Fang; Qiming Wang; Wenxiu Yao; Renhua Guo; Dongqing Lv; Shundong Cang; Xiaorong Dong; Huijuan Wang; Nong Yang; Yun Fan; Jiuwei Cui; Ziping Wang; Jianxing He; Yu S. Huang; Weizhi Chen; Li-Di Xu; Caicun Zhou
A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors

一项多中心，随机，双盲试验，比较生物仿制药LY01011与denosumab (Xgeva®) 实体瘤骨转移患者

JOURNAL OF BONE ONCOLOGY
IF3.5
2025-04-010
OAAI
Zhao, Mingchuan; Hu, Xichun; Zhuang, Pengpeng; Zeng, Aiping; Yu, Yan; Chen, Zhendong; Sun, Hongmei; Yang, Weihua; Sheng, Lili; Pengi, Peijian; Wang, Jingfen; Yi, Tienan; Bi, Minghong; Shim, Huaqiu; Ni, Mingli; Dai, Xiumei; Hu, Changlu; Xu, Hongjie; Lv, Dongqing; Lis, Qingshan; Lei, Kaijian; Yuan, Xia; Jiang, Ou; Wang, Xicheng; Hu, Baihui; Hou, Zhe; Su, Zhaoping; Zheng, Song; Zhou, Ming; Dou, Changlin
Real-world effectiveness and safety of fi rst-line (1L) osimertinib for EGFR-mutated (EGFRm) advanced NSCLC: A prospective, multi-center, real-world study in China (FLOURISH Study)

真实世界中EGFR突变（EGFRm）晚期非小细胞肺癌（NSCLC）患者一线（1L）奥希替尼的有效性与安全性：一项在中国进行的前瞻性、多中心、真实世界研究（FLOURISH研究）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Zhou, J.; Shen, L.; Lv, D.; Tang, K.; Zhu, D.; Zhao, Y.; Wang, K.; Wang, Y.; Xing, L.; Cui, J.; Ding, L.; Shi, X.; Zheng, J.
Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study
LANCET RESPIRATORY MEDICINE
IF32.8
2024-12-011
PRE
Yu, Yongfeng; Guo, Qisen; Zhang, Yongchang; Fang, Jian; Zhong, Diansheng; Liu, Baogang; Pan, Pinhua; Lv, Dongqing; Wu, Lin; Zhao, Yanqiu; Li, Juan; Liu, Zhihua; Liu, Chunling; Su, Haichuan; Fan, Yun; Zhang, Tongmei; Liu, Anwen; Jin, Bo; Wang, Ye; Zhou, Jianying; Zhang, Zhihong; Ran, Fengming; Song, Xia; Shi, Michael; Su, Weiguo; Lu, Shun
A phase I/II multicenter, first-in-human study of DB-1311/ BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors

一项关于DB-1311/BNT324（一种新型B7H3 ADC）在晚期实体瘤患者中的I/II期多中心、首次人体研究

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Cheng, Y.; Wu, L.; Parsonson, A.; Amin, H.; Shi, J.; Lemech, C.; Sun, Y.; Schmidt, A.; Lv, D.; Li, M.; Zheng, T.; Chaudhry, A.; Gandhi, C.; Wang, Q.; Motino, D. A. Montoya; Abed, A.; Tibes, R.; Lu, X.; Gu, V.; Lisberg, A. E.
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study

度伐鲁单抗与化疗作为肿瘤PD-L1表达≥25%的转移性非小细胞肺癌的一线治疗方案：随机III期PEARL研究的结果

JOURNAL OF THORACIC ONCOLOGY
IF20.8
2024-11-010
PRE
Lu, Shun; Wu, Lin; Wang, Qiming; Wang, Ziping; Lv, Dongqing; Ma, Rui; Zhu, Bo; Tran, Ngoc van; Jiang, Liyan; Nan, Kejun; Laktionov, Konstantin; Clarke, Stephen; Song, Minghao; Mann, Helen; Liu, Yinglei; Shi, Xiaojin
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial

Ivonescimab联合化疗治疗EGFR变异的非小细胞肺癌随机临床试验

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
IF55
2024-08-209
OA
Fang, Wenfeng; Zhao, Yuanyuan; Luo, Yongzhong; Yang, Runxiang; Huang, Yan; He, Zhiyong; Zhao, Hui; Li, Mingjun; Li, Kai; Song, Qibing; Du, Xiaobo; Sun, Yulan; Li, Wei; Xu, Fei; Wang, Zhiyu; Yang, Kunning; Fan, Yun; Liu, Baogang; Zhao, Hongyun; Hu, Ying; Jia, Li; Xu, Shen; Yi, Tienan; Lv, Dongqing; Lan, Haitao; Li, Mengxia; Liang, Wenhua; Wang, Yongsheng; Yang, Hui; Jia, Yuming; Chen, Yuan; Lu, Junguo; Feng, Jifeng; Liu, Chunling; Zhou, Ming; Zhou, Jianya; Liu, Xianling; Zhou, Ningning; He, Ming; Dong, Xiaorong; Chen, Hualin; Chen, Yongxing; Su, Haichuan; Li, Xiaoling; Zhang, Zhihong; Yang, Lei; Cheng, Ying; Chen, Likun; Hou, Xue; Zhang, Yu; Guo, Jun; Wang, Zhen; Lu, Hong; Wu, Di; Feng, Weineng; Li, Wen; Huang, Jianan; Wang, Yan; Song, Xia; Peng, Jiewen; Liu, Laiyu; Guo, Yubiao; Li, Wenting; Lu, Dongmei; Hu, Mingxiu; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Zhang, Li
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR-mutated, advanced non-small cell lung cancer: data from a randomized phase III trial (AENEAS)

未经治疗的EGFR突变的晚期非小细胞肺癌患者中奥罗替尼与吉非替尼的中枢神经系统疗效: 来自随机III期试验 (AENEAS) 的数据

CANCER COMMUNICATIONS
IF24.9
2024-07-170
OAAI
Lu, Shun; Dong, Xiaorong; Jian, Hong; Chen, Jianhua; Chen, Gongyan; Sun, Yuping; Ji, Yinghua; Wang, Ziping; Shi, Jianhua; Lu, Junguo; Chen, Shaoshui; Lv, Dongqing; Zhang, Guojun; Liu, Chunling; Li, Juan; Yu, Xinmin; Lin, Zhong; Yu, Zhuang; Wang, Zhehai; Cui, Jiuwei; Xu, Xingxiang; Fang, Jian; Feng, Jifeng; Xu, Zhi; Ma, Rui; Hu, Jie; Yang, Nong; Zhou, Xiangdong; Wu, Xiaohong; Hu, Chengping; Zhang, Zhihong; Lu, You; Hu, Yanping; Jiang, Liyan; Wang, Qiming; Guo, Renhua; Zhou, Jianying; Li, Baolan; Hu, Chunhong; Tong, Wancheng; Zhang, Helong; Ma, Lin; Chen, Yuan; Jie, Zhijun; Yao, Yu; Zhang, Longzhen; Weng, Jie; Li, Weidong; Xiong, Jianping; Ye, Xianwei; Duan, Jianchun; Yang, Haihua; Sun, Meili; Wei, Hongying; Wei, Jiawei; Zhang, Zheyu; Wu, Qiong
Open-label, single-arm, multicenter, phase 2 trial of garsorasib in KRAS G12C-mutated non-small-cell lung cancer
CANCER RESEARCH
IF16.6
2024-04-050
PRE
Li, Ziming; Dang, Xiaomin; Huang, Dingzhi; Jin, Shi; Li, Weiwei; Shi, Jianhua; Wang, Xicheng; Zhang, Yiping; Song, Zhengbo; Zhang, Junping; Zhuang, Wu; Liu, Xuewen; Jiang, Liyan; Meng, Xiangjiao; Zhao, Mingfang; Zhou, Jianying; Zhang, Liangming; Wang, Pingli; Luo, Hui; Yang, Junquan; Cang, Shundong; Wang, Xiang; Wang, Jing; Cui, Jiuwei; Yu, Yan; Zhang, Zhihong; Lu, Junguo; Yang, Weihua; Li, Gaofeng; Feng, Jifeng; Lv, Dongqing; Wu, Lin; Fang, Yong; Wang, Yan; Zhao, Yanqiu; Cao, Baoshan; Zhu, Wei; Zhuang, Zhixiang; Li, Qingshan; Wang, Mingxi; Zhou, Huan; Dong, Xiaorong; Hu, Sheng; Fang, Jian; Zhang, Yihong; Wang, Wenjia; Xiang, Ziyong; Shi, Zhe; Zhang, Ling; Lu, Shun

研究方向

暂未获取到该数据
程
程颖
H 指数:84论文数:1,042被引数:4.4万
L
Lin Wu
H 指数:59论文数:473被引数:1.7万
H
Haihua Yang
H 指数:35论文数:258被引数:7,070
陆
陆舜
H 指数:78论文数:904被引数:3.6万
J
Jianya Zhou
H 指数:22论文数:145被引数:1,948
J
Jianying Zhou
H 指数:66论文数:860被引数:2.4万
S
Shundong Cang
H 指数:36论文数:179被引数:7,174
J
Jian Fang
H 指数:35论文数:247被引数:6,355
R
Rongbin Qi
H 指数:3论文数:15被引数:56
Y
Yueyin Pan
H 指数:45论文数:286被引数:1.0万